Fig. 6

Overexpression of ARNTL2 sensitizes PC cells to erlotinib treatment. A-B Cell proliferation of ARNTL-vector, ARNTL2-OE PATU-8988 T and treated for 72 h with erlotinib at 2.5 μM, 5 μM and 10 μM, respectively; C-D ARNTL2 overexpression efficiency was measured by western blotting and q-PCR, respectively; E–F Colony-formation assay of ARNTL2-overexpression PATU-8988 T cells and control cells(NC) were grown in the absence or presence of erlotinib at the indicated concentrations for 7–10 days, fixed and stained; G Synergistic response to erlotinib treatment in ARNTL2-overexpression PATU-8988 T cells and control cells(NC); H IC50 assay of erlotinib in ARNTL2-overexpression PATU-8988 T cells and control cells(NC); I-J Flow cytometry analysis of erlotinib-induced cell apoptosis in ARNTL2-overexpression PATU-8988 T cells and control cells(NC) treated with erlotinib and stained with Annexin V-APC-633/PI. All data are presented as the mean ± SEM of triplicate experiments. *p < 0.05; **p < 0.01; ***p < 0.001 by repeated measures with Student’s t test